Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant pembrolizumab in high-risk postoperative acral melanoma
ChiCTR2200064502Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Nov 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in melanoma and acral lentiginous melanoma (ALM), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Progression-free survival. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
03
Conditions
melanomaacral lentiginous melanoma (ALM)
Beyond the preview
Go deeper on ChiCTR2200064502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064502.